What is the official website of Fresenius Kabi Polska ?

The official website of Fresenius Kabi Polska is https://www.fresenius-kabi.com/pl/.

What is Fresenius Kabi Polska's cybersecurity risk score?

Fresenius Kabi Polska has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Fresenius Kabi Polska experienced?

According to Rankiteo, Fresenius Kabi Polska currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Fresenius Kabi Polska been affected by any supply chain cyber incidents ?

According to Rankiteo, Fresenius Kabi Polska has been affected by a supply chain cyber incident involving Fresenius Kabi USA, with the incident ID FRE1781735374.

Does Fresenius Kabi Polska have SOC 2 Type 1 certification ?

According to Rankiteo, Fresenius Kabi Polska is not certified under SOC 2 Type 1.

Does Fresenius Kabi Polska have SOC 2 Type 2 certification ?

According to Rankiteo, Fresenius Kabi Polska does not hold a SOC 2 Type 2 certification.

Does Fresenius Kabi Polska comply with GDPR ?

According to Rankiteo, Fresenius Kabi Polska is not listed as GDPR compliant.

Does Fresenius Kabi Polska have PCI DSS certification ?

According to Rankiteo, Fresenius Kabi Polska does not currently maintain PCI DSS compliance.

Does Fresenius Kabi Polska comply with HIPAA ?

According to Rankiteo, Fresenius Kabi Polska is not compliant with HIPAA regulations.

Does Fresenius Kabi Polska have ISO 27001 certification ?

According to Rankiteo,Fresenius Kabi Polska is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Fresenius Kabi Polska operate in ?

Fresenius Kabi Polska operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Fresenius Kabi Polska have ?

Fresenius Kabi Polska employs approximately 126 people worldwide.

Does Fresenius Kabi Polska own any subsidiaries ?

Fresenius Kabi Polska presently has no subsidiaries across any sectors.

How many LinkedIn followers does Fresenius Kabi Polska have ?

Fresenius Kabi Polska's official LinkedIn profile has approximately 2,441 followers.

What is the NAICS classification code for Fresenius Kabi Polska ?

Fresenius Kabi Polska is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Fresenius Kabi Polska have a Crunchbase profile ?

No, Fresenius Kabi Polska does not have a profile on Crunchbase.

Does Fresenius Kabi Polska have a LinkedIn profile ?

Yes, Fresenius Kabi Polska maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fresenius-kabi-polska.

How many cybersecurity incidents has Fresenius Kabi Polska experienced ?

As of July 22, 2026, Rankiteo reports that Fresenius Kabi Polska has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Fresenius Kabi Polska have ?

Fresenius Kabi Polska has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has Fresenius Kabi Polska faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FKP

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Fresenius Kabi Polska Vendor Cyber Rating & Cyber Score

fresenius-kabi.com

Add Your Compliance Badge

Misją Fresenius Kabi jest #troska_o_życie. Zapewniamy dostęp do żywienia medycznego, płynów infuzyjnych, leków dożylnych, technologii infuzyjnej i transfuzyjnej. W portfolio posiadamy też leki biopodobne oraz ketoanalogi aminokwasów – wspierające terapię Przewlekłej Choroby Nerek w okresie poprzedzającym dializy. Za pośrednictwem spółki #DOM_Medica zapewniamy opiekę nad pacjentami domowymi w zakresie żywienia dojelitowego oraz wentylacji mechanicznej. Nasza #Wytwórnia_Płynów_Infuzyjnych w Kutnie jest największym w Polsce producentem płynów (w tym płynu wieloelektrolitowego o składzie zbliżonym do osocza: Optilyte), których znaczna część trafia do szpitali w całej Polsce, jak również glukozy, 0,9% NaCl, koloidów i antybiotyków.

FKP A.I CyberSecurity Scoring

Scoring History

FKP

Fresenius Kabi Polska CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Fresenius Kabi USA

Breach

100

1/2026

Fresenius Kabi ...

FRE1781735374

Fresenius Group

Ransomware

100

5/2020

FRE1770566194

Fresenius Kabi Pols...

Ransomware

05/2020

FRE2038291222

Loading…

A.I.

FKP Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FKP

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Polska in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Fresenius Kabi Polska in 2026.

Incident Types FKP vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Polska in 2026.

Incident History - FKP (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Fresenius Kabi Polska Subsidiaries

FKP

Pharmaceutical Manufacturing

Website: https://www.fresenius-kabi.com/pl/

Company Size: 126

Fresenius KabiPharmaceutical Manufacturing

Fresenius GroupHospitals and Health Care

Fresenius Digital TechnologyInformation Technology & Services

Fresenius Investor RelationsKrankenhäuser und Gesundheitseinrichtungen

Helios Health GmbHHospitals and Health Care

QuirónsaludWellness and Fitness Services

Helios Kliniken GmbHHospitals and Health Care

Fresenius Kabi BrasilPharmaceutical Manufacturing

Fresenius Kabi USAPharmaceutical Manufacturing

Fresenius Kabi FrancePharmaceutical Manufacturing

Fresenius Kabi UKPharmaceutical Manufacturing

MOTIV eLearningHospitals and Health Care

Fresenius Kabi ColombiaPharmaceutical Manufacturing

Fresenius Kabi EspañaPharmaceutical Manufacturing

Fresenius Kabi Asia PacificPharmaceutical Manufacturing

Fenwal, Inc., a Fresenius Kabi CompanyMedical Equipment Manufacturing

Fresenius Kabi EcuadorPharmaceutical Manufacturing

Fresenius Kabi CanadaPharmaceutical Manufacturing

Fresenius Kabi MedTech EuropeMedical Equipment Manufacturing

Fresenius Kabi EuropePharmaceutical Manufacturing

Fresenius Kabi ChilePharmaceutical Manufacturing

Fresenius Kabi ItaliaPharmaceutical Manufacturing

Fresenius Kabi AustriaPharmaceutical Manufacturing

Fresenius Kabi ArgentinaPharmaceutical Manufacturing

Fresenius Kabi Australia and New ZealandPharmaceutical Manufacturing

Fresenius Kabi Business ServicesAccounting

Fresenius Kabi DanmarkPharmaceutical Manufacturing

Fresenius Kabi South AfricaPharmaceutical Manufacturing

Fresenius Kabi IrelandPharmaceutical Manufacturing

Fresenius Kabi Viet Nam Pharmaceutical Manufacturing

Fresenius Kabi NetherlandsPharmaceutical Manufacturing

Fresenius Kabi SchweizPharmaceutical Manufacturing

Fresenius Kabi BelgiumPharmaceutical Manufacturing

Fresenius Kabi (Singapore) Pte Ltd, SingaporePharmaceutical Manufacturing

Fresenius Kabi Puerto RicoManufacturing

Unidos por la Nutrición Clínica MéxicoHospitals and Health Care

Fresenius Kabi MéxicoPharmaceutical Manufacturing

Loading…

Fresenius Kabi Polska Similar Companies

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Fresenius Kabi Polska CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-63261

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-72/388575

CVE-2026-63260

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-71/388574

CVE-2026-63259

SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-9-4-4-security-update-esa-2026-70/388573

CVE-2026-63145

SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-69/388572

CVE-2026-63144

SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-19-9-3-8-9-4-4-security-update-esa-2026-68/388571

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…